Compare GSK plc (GSK) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sprott Uranium Miners ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Sprott Uranium Miners ETF trades at $46.5 (market cap $1.87B). The key difference: GSK plc is far larger — about 49.1× Sprott Uranium Miners ETF's market cap, and GSK plc pays a 3.9% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Sprott Uranium Miners ETF for 61 Days on average.
| GSK | URNM | |
|---|---|---|
Market Cap | $91.88B | $1.87B |
Volume | 7,730,529 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $61.18 | $83.99 |
52-Week Low | $43.24 | $46.09 |
Typical Hold Time | 93 Days | 61 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
URNM (Sprott Uranium Miners ETF) trades at $46.09, down 3.72% today amid bearish technical signals. The ETF shows strong fundamental support from uranium's supply-demand imbalance and growing AI energy demand. Recent news highlights nuclear energy's resurgence, with uranium prices rising 21.25% over the past year according to Sprott Asset Management data from August 2026.
Long-term outlook remains positive due to structural uranium deficits and government nuclear investments, but short-term technical weakness and ETF volatility present near-term risks. The convergence of AI power demand and nuclear expansion creates substantial growth potential for uranium miners over the next decade.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
